בריפלקס PN 250

Țară: Israel

Limbă: ebraică

Sursă: Ministry of Health

Cumpara asta acum

Ingredient activ:

COAGULATION FACTOR II (HUMAN); COAGULATION FACTOR IX (HUMAN- RFIXFC); COAGULATION FACTOR VII (HUMAN); COAGULATION FACTOR X (HUMAN); PROTEIN C; PROTEIN S ANTIGEN

Disponibil de la:

CSL BEHRING LTD., ISRAEL

Codul ATC:

B02BD01

Forma farmaceutică:

אבקה וממס להכנת תמיסה להזרקה

Compoziție:

COAGULATION FACTOR II (HUMAN) 200 - 480 IU; COAGULATION FACTOR VII (HUMAN) 100 - 250 IU; COAGULATION FACTOR IX (HUMAN- RFIXFC) 200 - 310 IU; COAGULATION FACTOR X (HUMAN) 220 - 600 IU; PROTEIN C 150 - 450 IU; PROTEIN S ANTIGEN 120 - 380 IU

Calea de administrare:

תוך-ורידי

Tip de prescriptie medicala:

מרשם נדרש

Produs de:

CSL BEHRING GmbH, GERMANY

Grupul Terapeutică:

COAGULATION FACTOR IX, II, VII AND X IN COMBINATION

Zonă Terapeutică:

COAGULATION FACTOR IX, II, VII AND X IN COMBINATION

Indicații terapeutice:

-Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.

Data de autorizare:

2017-03-31

Documente în alte limbi

Prospect Prospect engleză 17-08-2016
Caracteristicilor produsului Caracteristicilor produsului engleză 13-09-2023

Vizualizați istoricul documentelor